Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses

International Journal of Biological Markers

Volumn 26, Issue 4, 2011, Pages 262-273

  Wang, Qi ^a   Li, Danrong ^a   Zhang, Wei ^a   Tang, Bujian ^a   Li, Qingdi Quentin ^b,c   Li, Li ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Benign pelvic masses; Biomarkers; CCL18; CXCL1; Diagnosis; Ovarian cancer; Protein expression; Serum proteomics

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE; CHEMOKINE CC2 MOTIF LIGAND 18; CXCL1 CHEMOKINE; UNCLASSIFIED DRUG;

ARTICLE; BENIGN TUMOR; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; EVALUATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PELVIS TUMOR; PROTEIN ANALYSIS; PROTEOMICS; SENSITIVITY AND SPECIFICITY;

ADULT; CASE-CONTROL STUDIES; CHEMOKINE CXCL1; CHEMOKINES, CC; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PELVIC INFLAMMATORY DISEASE; PELVIC NEOPLASMS; PROTEOMICS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84555208284     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2011.8616     Document Type: Article

References (44)

1. Zhang Z, Bast RC, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004; 64: 5882-90.
2. Deraco M, Baratti D, Laterza B. Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer. Eur J Surg Oncol 2011; 37: 4-9.
3. Johnatty SE, Beesley J, Paul J. ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin Cancer Res 2008; 14: 5594-601.
4. Moscova M, Marsh DJ, Baxter RC. Protein chip discovery of secreted proteins regulated by the phosphatidylinositol 3-kinase pathway in ovarian cancer cell lines. Cancer Res 2006; 66: 1376-83.
5. Sasaroli D, Coukos G, Scholler N. Beyond CA125: the coming of age of ovarian cancer biomarkers. Are we there yet? Biomark Med 2009; 3: 275-88.
6. Kim JH, Skates SJ, Uede T. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002; 287: 1671-9.
7. Menon U, Skates SJ, Lewis S. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 2005; 23: 7919-26.
8. Xu FJ, Ramakrishnan S, Daly L. Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. Am J Obstet Gynecol 1991; 165: 1356-62.
9. van Haaften-Day C, Shen Y, Xu F. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer 2001; 92: 2837-44.
10. Havrilesky LJ, Whitehead CM, Rubatt JM. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol 2008; 110: 374-82.
11. Cox J, Mann M. Is proteomics the new genomics? Cell 2007; 130: 395-8.
12. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002; 48: 1296-1304.
13. Adam BL, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a patternmatching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002; 62: 3609-14.
14. Yu Y, Chen S, Wang LS, et al. Prediction of pancreatic cancer by serum biomarkers using surface-enhanced laser desorption/ionization-based decision tree classification. Oncology 2005; 68: 79-86.
15. Schwegler EE, Cazares L, Steel LF, et al. SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology 2005; 41: 634-42.
16. Wu FX, Wang Q, Zhao YN. Identifying serological biomarkers of hepatocellular carcinoma using surface-enhanced laser desorption/ionization time of flight mass spectroscopy. Cancer Lett 2009; 279: 163-70.
17. Hutchens TW, Yip TT. New desorption strategies for the mass spectrometric analysis of micromolecules. Rapid Commun Mass Spectrom 1993; 7: 576-80.
18. Fung ET, Thulasiraman V, Weinberger SR, Dalmasso EA. Protein biochips for differential profiling. Curr Opin Biotechnol 2001; 12: 65-9.
19. Metz CE. Basic principles of ROC analysis. Semin Nucl Med 1978; 8: 283-98.
20. Rai AJ, Zhang Z, Rosenzweig J. Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med 2002; 126: 1518-26.
21. Poon TC, Yip TT, Chan AT, et al. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem 2003; 49: 752-60.
22. Petricoin EF, Liotta LA. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol 2004; 15: 24-30.
23. Pepe MS, Etzioni R, Feng Z. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001; 93: 1054-61.
24. Hellstrom I, Raycraft J, Hayden-Ledbetter M. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003; 63: 3695-700.
25. Gubbels JA, Belisle J, Onda M. Mesothelin-MUC16binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 2006; 5: 50-6.
26. Kryczek I, Zou L, Rodriguez P. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006; 203: 871-81.
27. Mok SC, Chao J, Skates S. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst 2001; 93: 1458-64.
28. Matrisian LM, Sledge GW, Mohla S. Extracellular proteolysis and cancer: meeting summary and future directions. Cancer Res 2003; 63: 6105-9.
29. Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev 2000; 22: 184-204.
30. Zhang W, Yang HC, Wang Q, et al. Clinical value of combined detection of serum matrix metalloproteinase-9, heparanase, and cathepsin for determining ovarian cancer invasion and metastasis. Anticancer Res 2011 (in press).
31. Adema GJ, Hartgers F, Verstraten R, et al. A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells. Nature 1997; 387: 713-7.
32. Hieshima K, Imai T, Baba M, et al. A novel human CC chemokine PARC that is most homologous to macrophage-inflammatory protein-1 alpha/LD78 alpha and chemotactic for T lymphocytes, but not for monocytes. J Immunol 1997; 159: 1140-9.
33. Kodelja V, Muller C, Politz O, Hakij N, Orfanos CE, Goerdt S. Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern. J Immunol 1998; 160: 1411-8.
34. Atamas SP, Luzina IG, Choi J, et al. Pulmonary and activation-regulated chemokine stimulates collagen production in lung fibroblasts. Am J Respir Cell Mol Biol 2003; 29: 743-9.
35. Schutyser E, Struyf S, Proost P, et al. Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J Biol Chem 2002; 277: 24584-93.
36. Zohny SF, Fayed ST. Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer. Med Oncol 2010; 27: 1246-53.
37. Bordoni R, Fine R, Murray D, Richmond A. Characterization of the role of melanoma growth stimulatory activity (MGSA) in the growth of normal melanocytes, nevocytes, and malignant melanocytes. Cell Biochem 1990; 44: 207-19.
38. Balentien E, Mufson BE, Shattuck RL, Derynck R, Richmond A. Effects of MGSA/GRO alpha on melanocyte transformation. Oncogene 1991; 6: 1115-24.
39. Wang D, Yang W, Du J, et al. MGSA/GRO-mediated melanocyte transformation involves induction of Rasexpression. Oncogene 2000; 19: 4647-59.
40. Yang G, Rosen DG, Zhang Z, et al. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci USA 2006; 103: 16472-7.
41. Woolas RP, Conaway MR, Xu F. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 1995; 59: 111-6.
42. Skates SJ, Pauler DK, Jacobs I. Screening based on the risk of cancer calculation from Bayesian hierarchical changepoint and mixture models of longitudinal markers. J Am Stat Assoc 2001; 96: 429-39.
43. Diamandis EP. Cancer biomarkers: can we turn recent failures into success? J Natl Cancer Inst 2010; 102: 1462-7.
44. Cramer DW, Bast RC, Berg CD, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res 2011; 4: 365-74.